Annual report pursuant to Section 13 and 15(d)

License and Agreements - Additional Information (Detail)

v3.2.0.727
License and Agreements - Additional Information (Detail)
 12 Months Ended
Dec. 31, 2015
GBP (£)
Dec. 31, 2015
USD ($)
Oct. 16, 2012
USD ($)
May. 31, 2015
GBP (£)
May. 31, 2015
USD ($)
Jun. 30, 2016
GBP (£)
Jun. 30, 2016
USD ($)
Commitments and Contingencies [Line Items]              
Asset purchase, cash paid     $ 3,500,000        
Asset Purchase Agreement Aggregate Consideration Paying Period       10 years 10 years    
Accrued milestone payments         $ 2,500,000    
Accrued license fees         $ 930,000    
Annual license fee | £       £ 300,000      
Progenics Pharmaceuticals, Inc.              
Commitments and Contingencies [Line Items]              
Royalty on every net sales         5.00%    
Scenario, Forecast              
Commitments and Contingencies [Line Items]              
License payment £ 600,000 $ 930,000          
Maximum contingent payment           £ 600,000 $ 930,000
Milestone Payments | US Phase III trial              
Commitments and Contingencies [Line Items]              
Asset purchase, cash paid         $ 1,500,000    
Milestone Payments | US new drug application approval by the FDA              
Commitments and Contingencies [Line Items]              
Asset purchase, cash paid         $ 5,000,000    
Development Milestone Payments              
Commitments and Contingencies [Line Items]              
Royalty on every net sales         7.50%    
Asset Purchase Agreement Aggregate Consideration Paying Period       10 years 10 years    
Minimum annual license maintenance fees         $ 150,000    
Development Milestone Payments | US Phase III trial              
Commitments and Contingencies [Line Items]              
Asset purchase, cash paid         1,000,000    
Development Milestone Payments | US new drug application approval by the FDA              
Commitments and Contingencies [Line Items]              
Asset purchase, cash paid         500,000    
Development Milestone Payments | New Drug Application with the FDA              
Commitments and Contingencies [Line Items]              
Asset purchase, cash paid         $ 500,000